The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease

SLAGEN Consortium; Christina M. Lill; Aina Rengmark; Lasse Pihlstrøm; Isabella Fogh; Aleksey Shatunov; Patrick M. Sleiman; Li San Wang; Tian Liu; Christina F. Lassen; Esther Meissner; Panos Alexopoulos; Andrea Calvo; Adriano Chio; Nil Dizdar; Frank Faltraco; Lars Forsgren; Julia Kirchheiner; Alexander Kurz; Jan P. Larsen; Maria Liebsch; Jan Linder; Karen E. Morrison; Hans Nissbrandt; Markus Otto; Jens Pahnke; Amanda Partch; Gabriella Restagno; Dan Rujescu; Cathrin Schnack; Christopher E. Shaw; Pamela J. Shaw; Hayrettin Tumani; Ole Bjørn Tysnes; Otto Valladares; Vincenzo Silani; Leonard H. Van Den Berg; Wouter Van Rheenen; Jan H. Veldink; Ulman Lindenberger; Elisabeth Steinhagen-Thiessen; Stefan Teipel; Robert Perneczky; Hakon Hakonarson; Harald Hampel; Christine A.F. Von Arnim; Jørgen H. Olsen; Vivianna M. Van Deerlin; Ammar Al-Chalabi; Mathias Toft; Lars Bertram

doi:10.1016/j.jalz.2014.12.009

The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease

SLAGEN Consortium, Christina M. Lill^*, Aina Rengmark, Lasse Pihlstrøm, Isabella Fogh, Aleksey Shatunov, Patrick M. Sleiman, Li San Wang, Tian Liu, Christina F. Lassen, Esther Meissner, Panos Alexopoulos, Andrea Calvo, Adriano Chio, Nil Dizdar, Frank Faltraco, Lars Forsgren, Julia Kirchheiner, Alexander Kurz, Jan P. LarsenMaria Liebsch, Jan Linder, Karen E. Morrison, Hans Nissbrandt, Markus Otto, Jens Pahnke, Amanda Partch, Gabriella Restagno, Dan Rujescu, Cathrin Schnack, Christopher E. Shaw, Pamela J. Shaw, Hayrettin Tumani, Ole Bjørn Tysnes, Otto Valladares, Vincenzo Silani, Leonard H. Van Den Berg, Wouter Van Rheenen, Jan H. Veldink, Ulman Lindenberger, Elisabeth Steinhagen-Thiessen, Stefan Teipel, Robert Perneczky, Hakon Hakonarson, Harald Hampel, Christine A.F. Von Arnim, Jørgen H. Olsen, Vivianna M. Van Deerlin, Ammar Al-Chalabi, Mathias Toft, Lars Bertram

^*Corresponding author for this work

50 Citations (Scopus)

Abstract

A rare variant in TREM2 (p.R47H, rs75932628) was recently reported to increase the risk of Alzheimer's disease (AD) and, subsequently, other neurodegenerative diseases, i.e. frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Here we comprehensively assessed TREM2 rs75932628 for association with these diseases in a total of 19,940 previously untyped subjects of European descent. These data were combined with those from 28 published data sets by meta-analysis. Furthermore, we tested whether rs75932628 shows association with amyloid beta (Aβ₄₂) and total-tau protein levels in the cerebrospinal fluid (CSF) of 828 individuals with AD or mild cognitive impairment. Our data show that rs75932628 is highly significantly associated with the risk of AD across 24,086 AD cases and 148,993 controls of European descent (odds ratio or OR = 2.71, P = 4.67 × 10^-25). No consistent evidence for association was found between this marker and the risk of FTLD (OR = 2.24, P = .0113 across 2673 cases/9283 controls), PD (OR = 1.36, P = .0767 across 8311 cases/79,938 controls) and ALS (OR = 1.41, P = .198 across 5544 cases/7072 controls). Furthermore, carriers of the rs75932628 risk allele showed significantly increased levels of CSF-total-tau (P = .0110) but not Aβ₄₂ suggesting that TREM2's role in AD may involve tau dysfunction.

Original language	English
Journal	Alzheimer's and Dementia
Volume	11
Issue number	12
Pages (from-to)	1407-1416
Number of pages	10
ISSN	1552-5260
DOIs	https://doi.org/10.1016/j.jalz.2014.12.009
Publication status	Published - 01.12.2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jalz.2014.12.009

Cite this

SLAGEN Consortium, Lill, C. M., Rengmark, A., Pihlstrøm, L., Fogh, I., Shatunov, A., Sleiman, P. M., Wang, L. S., Liu, T., Lassen, C. F., Meissner, E., Alexopoulos, P., Calvo, A., Chio, A., Dizdar, N., Faltraco, F., Forsgren, L., Kirchheiner, J., Kurz, A., ... Bertram, L. (2015). The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's and Dementia, 11(12), 1407-1416. https://doi.org/10.1016/j.jalz.2014.12.009

@article{6cb63997db9a40dba59752388a95a411,

title = "The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease",

abstract = "A rare variant in TREM2 (p.R47H, rs75932628) was recently reported to increase the risk of Alzheimer's disease (AD) and, subsequently, other neurodegenerative diseases, i.e. frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Here we comprehensively assessed TREM2 rs75932628 for association with these diseases in a total of 19,940 previously untyped subjects of European descent. These data were combined with those from 28 published data sets by meta-analysis. Furthermore, we tested whether rs75932628 shows association with amyloid beta (Aβ42) and total-tau protein levels in the cerebrospinal fluid (CSF) of 828 individuals with AD or mild cognitive impairment. Our data show that rs75932628 is highly significantly associated with the risk of AD across 24,086 AD cases and 148,993 controls of European descent (odds ratio or OR = 2.71, P = 4.67 × 10-25). No consistent evidence for association was found between this marker and the risk of FTLD (OR = 2.24, P = .0113 across 2673 cases/9283 controls), PD (OR = 1.36, P = .0767 across 8311 cases/79,938 controls) and ALS (OR = 1.41, P = .198 across 5544 cases/7072 controls). Furthermore, carriers of the rs75932628 risk allele showed significantly increased levels of CSF-total-tau (P = .0110) but not Aβ42 suggesting that TREM2's role in AD may involve tau dysfunction.",

author = "{SLAGEN Consortium} and Lill, {Christina M.} and Aina Rengmark and Lasse Pihlstr{\o}m and Isabella Fogh and Aleksey Shatunov and Sleiman, {Patrick M.} and Wang, {Li San} and Tian Liu and Lassen, {Christina F.} and Esther Meissner and Panos Alexopoulos and Andrea Calvo and Adriano Chio and Nil Dizdar and Frank Faltraco and Lars Forsgren and Julia Kirchheiner and Alexander Kurz and Larsen, {Jan P.} and Maria Liebsch and Jan Linder and Morrison, {Karen E.} and Hans Nissbrandt and Markus Otto and Jens Pahnke and Amanda Partch and Gabriella Restagno and Dan Rujescu and Cathrin Schnack and Shaw, {Christopher E.} and Shaw, {Pamela J.} and Hayrettin Tumani and Tysnes, {Ole Bj{\o}rn} and Otto Valladares and Vincenzo Silani and {Van Den Berg}, {Leonard H.} and {Van Rheenen}, Wouter and Veldink, {Jan H.} and Ulman Lindenberger and Elisabeth Steinhagen-Thiessen and Stefan Teipel and Robert Perneczky and Hakon Hakonarson and Harald Hampel and {Von Arnim}, {Christine A.F.} and Olsen, {J{\o}rgen H.} and {Van Deerlin}, {Vivianna M.} and Ammar Al-Chalabi and Mathias Toft and Lars Bertram",

year = "2015",

month = dec,

day = "1",

doi = "10.1016/j.jalz.2014.12.009",

language = "English",

volume = "11",

pages = "1407--1416",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

number = "12",

}

SLAGEN Consortium, Lill, CM, Rengmark, A, Pihlstrøm, L, Fogh, I, Shatunov, A, Sleiman, PM, Wang, LS, Liu, T, Lassen, CF, Meissner, E, Alexopoulos, P, Calvo, A, Chio, A, Dizdar, N, Faltraco, F, Forsgren, L, Kirchheiner, J, Kurz, A, Larsen, JP, Liebsch, M, Linder, J, Morrison, KE, Nissbrandt, H, Otto, M, Pahnke, J, Partch, A, Restagno, G, Rujescu, D, Schnack, C, Shaw, CE, Shaw, PJ, Tumani, H, Tysnes, OB, Valladares, O, Silani, V, Van Den Berg, LH, Van Rheenen, W, Veldink, JH, Lindenberger, U, Steinhagen-Thiessen, E, Teipel, S, Perneczky, R, Hakonarson, H, Hampel, H, Von Arnim, CAF, Olsen, JH, Van Deerlin, VM, Al-Chalabi, A, Toft, M & Bertram, L 2015, 'The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease', Alzheimer's and Dementia, vol. 11, no. 12, pp. 1407-1416. https://doi.org/10.1016/j.jalz.2014.12.009

The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. / SLAGEN Consortium; Lill, Christina M.; Rengmark, Aina et al.
In: Alzheimer's and Dementia, Vol. 11, No. 12, 01.12.2015, p. 1407-1416.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease

AU - SLAGEN Consortium

AU - Lill, Christina M.

AU - Rengmark, Aina

AU - Pihlstrøm, Lasse

AU - Fogh, Isabella

AU - Shatunov, Aleksey

AU - Sleiman, Patrick M.

AU - Wang, Li San

AU - Liu, Tian

AU - Lassen, Christina F.

AU - Meissner, Esther

AU - Alexopoulos, Panos

AU - Calvo, Andrea

AU - Chio, Adriano

AU - Dizdar, Nil

AU - Faltraco, Frank

AU - Forsgren, Lars

AU - Kirchheiner, Julia

AU - Kurz, Alexander

AU - Larsen, Jan P.

AU - Liebsch, Maria

AU - Linder, Jan

AU - Morrison, Karen E.

AU - Nissbrandt, Hans

AU - Otto, Markus

AU - Pahnke, Jens

AU - Partch, Amanda

AU - Restagno, Gabriella

AU - Rujescu, Dan

AU - Schnack, Cathrin

AU - Shaw, Christopher E.

AU - Shaw, Pamela J.

AU - Tumani, Hayrettin

AU - Tysnes, Ole Bjørn

AU - Valladares, Otto

AU - Silani, Vincenzo

AU - Van Den Berg, Leonard H.

AU - Van Rheenen, Wouter

AU - Veldink, Jan H.

AU - Lindenberger, Ulman

AU - Steinhagen-Thiessen, Elisabeth

AU - Teipel, Stefan

AU - Perneczky, Robert

AU - Hakonarson, Hakon

AU - Hampel, Harald

AU - Von Arnim, Christine A.F.

AU - Olsen, Jørgen H.

AU - Van Deerlin, Vivianna M.

AU - Al-Chalabi, Ammar

AU - Toft, Mathias

AU - Bertram, Lars

PY - 2015/12/1

Y1 - 2015/12/1

N2 - A rare variant in TREM2 (p.R47H, rs75932628) was recently reported to increase the risk of Alzheimer's disease (AD) and, subsequently, other neurodegenerative diseases, i.e. frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Here we comprehensively assessed TREM2 rs75932628 for association with these diseases in a total of 19,940 previously untyped subjects of European descent. These data were combined with those from 28 published data sets by meta-analysis. Furthermore, we tested whether rs75932628 shows association with amyloid beta (Aβ42) and total-tau protein levels in the cerebrospinal fluid (CSF) of 828 individuals with AD or mild cognitive impairment. Our data show that rs75932628 is highly significantly associated with the risk of AD across 24,086 AD cases and 148,993 controls of European descent (odds ratio or OR = 2.71, P = 4.67 × 10-25). No consistent evidence for association was found between this marker and the risk of FTLD (OR = 2.24, P = .0113 across 2673 cases/9283 controls), PD (OR = 1.36, P = .0767 across 8311 cases/79,938 controls) and ALS (OR = 1.41, P = .198 across 5544 cases/7072 controls). Furthermore, carriers of the rs75932628 risk allele showed significantly increased levels of CSF-total-tau (P = .0110) but not Aβ42 suggesting that TREM2's role in AD may involve tau dysfunction.

AB - A rare variant in TREM2 (p.R47H, rs75932628) was recently reported to increase the risk of Alzheimer's disease (AD) and, subsequently, other neurodegenerative diseases, i.e. frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Here we comprehensively assessed TREM2 rs75932628 for association with these diseases in a total of 19,940 previously untyped subjects of European descent. These data were combined with those from 28 published data sets by meta-analysis. Furthermore, we tested whether rs75932628 shows association with amyloid beta (Aβ42) and total-tau protein levels in the cerebrospinal fluid (CSF) of 828 individuals with AD or mild cognitive impairment. Our data show that rs75932628 is highly significantly associated with the risk of AD across 24,086 AD cases and 148,993 controls of European descent (odds ratio or OR = 2.71, P = 4.67 × 10-25). No consistent evidence for association was found between this marker and the risk of FTLD (OR = 2.24, P = .0113 across 2673 cases/9283 controls), PD (OR = 1.36, P = .0767 across 8311 cases/79,938 controls) and ALS (OR = 1.41, P = .198 across 5544 cases/7072 controls). Furthermore, carriers of the rs75932628 risk allele showed significantly increased levels of CSF-total-tau (P = .0110) but not Aβ42 suggesting that TREM2's role in AD may involve tau dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=84952631227&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2014.12.009

DO - 10.1016/j.jalz.2014.12.009

M3 - Journal articles

C2 - 25936935

AN - SCOPUS:84952631227

SN - 1552-5260

VL - 11

SP - 1407

EP - 1416

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 12

ER -

The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this